| Standing the test of time: targeting thymidylate biosynthesis in cancer therapy PM Wilson, PV Danenberg, PG Johnston, HJ Lenz, RD Ladner Nature reviews Clinical oncology 11 (5), 282-298, 2014 | 553 | 2014 |
| Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models Y Ning, PC Manegold, YK Hong, W Zhang, A Pohl, G Lurje, T Winder, ... International journal of cancer 128 (9), 2038-2049, 2011 | 532 | 2011 |
| Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan J Boyer, EG McLean, S Aroori, P Wilson, A McCulla, PD Carey, ... Clinical cancer research 10 (6), 2158-2167, 2004 | 283 | 2004 |
| A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with … W Zhang, T Winder, Y Ning, A Pohl, D Yang, M Kahn, G Lurje, MJ Labonte, ... Annals of Oncology 22 (1), 104-109, 2011 | 177 | 2011 |
| Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer J Boyer, WL Allen, EG McLean, PM Wilson, A McCulla, S Moore, ... Cancer research 66 (5), 2765-2777, 2006 | 135 | 2006 |
| Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer … G Lurje, F Nagashima, W Zhang, D Yang, HM Chang, MA Gordon, ... Clinical Cancer Research 14 (23), 7884-7895, 2008 | 134 | 2008 |
| Common cancer stem cell gene variants predict colon cancer recurrence A Gerger, W Zhang, D Yang, P Bohanes, Y Ning, T Winder, MJ LaBonte, ... Clinical Cancer Research 17 (21), 6934-6943, 2011 | 109 | 2011 |
| DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines MJ LaBonte, PM Wilson, W Fazzone, S Groshen, HJ Lenz, RD Ladner BMC medical genomics 2, 1-20, 2009 | 108 | 2009 |
| Molecular markers in the treatment of metastatic colorectal cancer PM Wilson, MJ LaBonte, HJ Lenz The Cancer Journal 16 (3), 262-272, 2010 | 107 | 2010 |
| A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates PM Wilson, MJ LaBonte, J Russell, S Louie, AA Ghobrial, RD Ladner Nucleic acids research 39 (17), e112-e112, 2011 | 106 | 2011 |
| Novel opportunities for thymidylate metabolism as a therapeutic target PM Wilson, W Fazzone, MJ LaBonte, J Deng, N Neamati, RD Ladner Molecular cancer therapeutics 7 (9), 3029-3037, 2008 | 105 | 2008 |
| Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer A Gerger, A El-Khoueiry, W Zhang, D Yang, H Singh, P Bohanes, Y Ning, ... Clinical Cancer Research 17 (17), 5783-5792, 2011 | 104 | 2011 |
| The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models MJ LaBonte, PM Wilson, W Fazzone, J Russell, SG Louie, A El-Khoueiry, ... Cancer research 71 (10), 3635-3648, 2011 | 99 | 2011 |
| Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells W Fazzone, PM Wilson, MJ LaBonte, HJ Lenz, RD Ladner International Journal of Cancer 125 (2), 463-473, 2009 | 93 | 2009 |
| Inhibition of dUTPase induces synthetic lethality with thymidylate synthase–targeted therapies in non–small cell lung cancer PM Wilson, MJ LaBonte, HJ Lenz, PC Mack, RD Ladner Molecular cancer therapeutics 11 (3), 616-628, 2012 | 82 | 2012 |
| Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage PM Wilson, W Fazzone, MJ LaBonte, HJ Lenz, RD Ladner Nucleic acids research 37 (1), 78-95, 2009 | 66 | 2009 |
| Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients T Winder, W Zhang, D Yang, Y Ning, P Bohanes, A Gerger, PM Wilson, ... Clinical Cancer Research 16 (22), 5591-5602, 2010 | 65 | 2010 |
| The role of spermidine/spermine N1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells WL Allen, EG McLean, J Boyer, A McCulla, PM Wilson, V Coyle, ... Molecular cancer therapeutics 6 (1), 128-137, 2007 | 64 | 2007 |
| A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy PM Wilson, A El-Khoueiry, S Iqbal, W Fazzone, MJ LaBonte, S Groshen, ... Cancer chemotherapy and pharmacology 65, 979-988, 2010 | 62 | 2010 |
| Calbindin 2 (CALB2) regulates 5-fluorouracil sensitivity in colorectal cancer by modulating the intrinsic apoptotic pathway L Stevenson, WL Allen, I Proutski, G Stewart, L Johnston, K McCloskey, ... PloS one 6 (5), e20276, 2011 | 47 | 2011 |
